MAY 26, 2017 10:49 AM PDT

FDA Approved Cancer Drug Based on Mutation, Not Location

WRITTEN BY: Xuan Pham

For the first time, the US FDA approved a cancer drug for patients based on presence of genetic biomarkers. Whereas cancer drugs have been traditionally been approved based on the location of the tumor, Keytruda (pembrolizumab) is approved for cancer patients with genetic defects classified as “microsatellite instability” or “mismatch repair” deficiencies.

"KEYTRUDA binds to the PD-­1 receptor and blocks its interaction with PD-­L1 and PD-­L2, which helps restore the immune response." - Keytruda.com

"This is an important first for the cancer community," said Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence. "Until now, the FDA has approved cancer treatments based on where in the body the cancer started - for example, lung or breast cancers. We have now approved a drug based on a tumor's biomarker without regard to the tumor's original location."

Keytruda is a humanized antibody that works as a second-line immunotherapy agent to destroy the cancer. This drug targets the programmed cell death 1 (PD-1) receptor, a protein that’s responsible for preventing the immune system from attacking its own cells. Cancers can take advantage of this system by making its own proteins that bind to PD-1, which shuts down the body’s ability to kill the cancer. As an immunotherapy, pembrolizumab boosts the body’s ability to kill the cancer again. The drug is already approved for the treatment of several types of cancer, including non-small cell lung cancer, melanoma, and some head and neck cancers, and even mesothelioma.

But the new approval could significantly expand uses of this drug. In particular, Keytruda may now be used to treat any solid tumor as long as the patients have the indicated biomarkers: microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR). These types of deficiencies are estimated to be present in about 4 percent of cancers, including colorectal, endometrial, and gastrointestinal cancers.

Notably, the drug’s new indication would expand access to cancer patients with solid tumors that have progressed despite treatment and for which there are no other therapy. For colorectal cancer, this means patients who have exhausted their chemotherapy defenses with drugs such as fluoropyrimidine, oxaliplatin, and irinotecan, Keytruda can be a new option.

“The FDA’s approval of this new indication for Keytruda further supports Merck’s commitment to helping people with difficult-to-treat cancers,” said Roger M. Perlmutter, president of Merck Research Laboratories, the drug’s manufacturer.

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 11, 2018
Cannabis Sciences
SEP 11, 2018
New Evidence Shows Marijuana Smoke is Not the Same as Cigarette Smoke, at Least, in Terms of Lung Disease.
A recent report published in the journal Breathe by scientists in the UK suggests that chronic marijuana smoking may not cause the same deleterious effects...
OCT 04, 2018
Videos
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
NOV 12, 2018
Health & Medicine
NOV 12, 2018
Researchers find that obesity has a paradoxical effect on Cancer
Cancer therapy works differently in different people. Understanding what effects the individual body's response to treatment will be crucial for the development...
NOV 14, 2018
Immunology
NOV 14, 2018
Rapid Tumor Targeting
Researchers at the University of California Irvine have developed a technology that will rapidly identify and target T cell receptors for tumor specific antigens...
DEC 04, 2018
Drug Discovery
DEC 04, 2018
Drug Combination May Be Effective for Melanoma
Protein kinase inhibitors have been noted to be the most effective class of drugs in the treatment of melanoma—a deadly skin cancer of the melanocyte...
Loading Comments...